Barratt G, Puisieux F, Yu W P, Foucher C, Fessi H, Devissaguet J P
URA CNRS 1218, Physico-Chimie, Pharmacotechnie, Biopharmacie, Université de Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France.
Int J Immunopharmacol. 1994 May-Jun;16(5-6):457-61. doi: 10.1016/0192-0561(94)90036-1.
A lipophilic immunomodulator (MTP-Chol) was included in nanocapsules prepared from different polymers and the anti-metastatic effects of the resulting drug delivery systems were evaluated in a murine model of liver metastases. Loaded nanocapsules were effective if they were given 2 days before tumor inoculation. Neither the nature of the polymer nor the total dose of immunomodulator affected the antimetastatic capacity. However, enhanced anti-metastatic activity was obtained when indomethacin nanocapsules were associated with MTP-Chol nanocapsules. These results show that nanocapsules containing an immunomodulator possess anti-metastatic activity, but only when given as a prophylactic treatment; this would correspond, in the clinic, to patients undergoing surgery for a primary tumor and at risk of developing liver metastases.
一种亲脂性免疫调节剂（MTP-胆固醇）被包裹在由不同聚合物制备的纳米胶囊中，并在肝转移小鼠模型中评估了所得药物递送系统的抗转移作用。如果在肿瘤接种前两天给予负载纳米胶囊，则其是有效的。聚合物的性质和免疫调节剂的总剂量均不影响抗转移能力。然而，当吲哚美辛纳米胶囊与MTP-胆固醇纳米胶囊联合使用时，可获得增强的抗转移活性。这些结果表明，含有免疫调节剂的纳米胶囊具有抗转移活性，但仅在作为预防性治疗给药时才有效；在临床上，这将对应于接受原发性肿瘤手术且有发生肝转移风险的患者。
